Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies

BACKGROUND: Novel systemic therapies have improved response rates and survival in metastatic renal cell cancer (mRCC) and are considered standard of care for this entity. However, complete remission (CR) is rare and often oligoprogression is observed. Here, we analyse the role of surgery for oligopr...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Uyen-Thao, Passlick, Bernward, Schmid, Severin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089849/
https://www.ncbi.nlm.nih.gov/pubmed/37065601
http://dx.doi.org/10.21037/jtd-22-1120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089849/
https://www.ncbi.nlm.nih.gov/pubmed/37065601
http://dx.doi.org/10.21037/jtd-22-1120

Ejemplares similares